wordcreek24
About
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A new Japan, multicenter, phase 1/2, security along with efficacy research.
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A new Japan, multicenter, phase 1/2, security along with efficacy research.